Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MET-1
- Development stage
- Phase 1
- Lead developer
- NuBiyota
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
**MET-1** is a defined, stool-derived live microbial consortium originally developed as the synthetic-stool product RePOOPulate for recurrent *Clostridioides difficile* infection. It comprises 33 cultured bacterial strains isolated from a healthy human donor and was administered by colonoscopic instillation in an initial two-patient proof-of-principle study, in which both patients with recurrent infection remained symptom-free through six months of follow-up. Its intended therapeutic action is restoration of protective gut-community functions and colonization resistance, with preclinical evidence that the consortium can attenuate *C. difficile* toxin A-mediated epithelial injury. NuBiyota subsequently advanced microbial ecosystem therapeutics and entered a gastrointestinal-development collaboration with Takeda. ([europepmc.org](https://europepmc.org/articles/PMC3869191))
- Other names
- RePOOPulateMicrobial Ecosystem Therapeutic 1
02
Targets
TcdA (Clostridioides difficile toxin A)TcdB (Clostridioides difficile large clostridial toxin family)
Beyond the preview
Go deeper on MET-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MET-1.